Takeda to invest $1.2bn in Innovent Biologics.

Takeda, a company which focuses on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology, agreed to invest $1.2bn in Innovent Biologics, a biopharmaceutical company based in China, focused on developing, manufacturing and commercializing high-quality medicines for various diseases, including oncology and autoimmune disorders. “We believe that developing innovative immuno-oncology and ADC therapies will be key for redefining cancer treatment worldwide. We look forward to partnering with Takeda to maximize the potential of our pipeline for patients with a wide variety of cancers,” Dr. Hui Zhou, Innovent Biologics Chief R&D Officer for Oncology Pipeline.